Proton pump inhibitors and gastroenteritis

European Journal of Epidemiology

Volumn 31, Issue 10, 2016, Pages 1057-1063

  Hassing, Robert Jan ^a,b   Verbon, Annelies ^a   de Visser, Herman ^c   Hofman, Albert ^a   Stricker, Bruno H ^a,d  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b RIJNSTATE HOSPITAL   (Netherlands)

^c Star Medisch Diagnostisch Centrum   (Netherlands)

^d Netherlands Health Care Inspectorate   (Netherlands)

Author keywords

Campylobacter; Cohort study; Gastroenteritis; Proton pump inhibitor; Salmonella

Indexed keywords

PROTON PUMP INHIBITOR;

AGED; ARTICLE; CAMPYLOBACTER; CASE CONTROL STUDY; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; GASTROENTERITIS; HUMAN; MAJOR CLINICAL STUDY; MALE; PARASITE ISOLATION; PROSPECTIVE STUDY; SALMONELLA; SENSITIVITY ANALYSIS; SEX DIFFERENCE; SHIGELLA SONNEI; YERSINIA; CAMPYLOBACTERIOSIS; CHEMICALLY INDUCED; FECES; MICROBIOLOGY; MIDDLE AGED; SALMONELLOSIS; SHIGELLOSIS; YERSINIA INFECTION;

AGED; CAMPYLOBACTER INFECTIONS; CASE-CONTROL STUDIES; DYSENTERY, BACILLARY; FECES; FEMALE; GASTROENTERITIS; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PROTON PUMP INHIBITORS; SALMONELLA INFECTIONS; YERSINIA INFECTIONS;

EID: 84960394775     PISSN: 03932990     EISSN: 15737284     Source Type: Journal    
DOI: 10.1007/s10654-016-0136-8     Document Type: Article

References (33)

1. Neal KR, Scott HM, Slack RC, Logan RF. Omeprazole as a risk factor for campylobacter gastroenteritis: case–control study. BMJ. 1996;312:414–5.
2. Neal KR, Slack RC. Diabetes mellitus, anti-secretory drugs and other risk factors for campylobacter gastro-enteritis in adults: a case–control study. Epidemiol Infect. 1997;119:307–11.
3. Garcia Rodriguez LA, Ruigomez A, Panes J. Use of acid-suppressing drugs and the risk of bacterial gastroenteritis. Clin Gastroenterol Hepatol. 2007;5:1418–23.
4. Doorduyn Y, Van Pelt W, Siezen CL, Van Der Horst F, Van Duynhoven YT, Hoebee B, et al. Novel insight in the association between salmonellosis or campylobacteriosis and chronic illness, and the role of host genetics in susceptibility to these diseases. Epidemiol Infect. 2008;136:1225–34.
5. Doorduyn Y, Van Den Brandhof WE, Van Duynhoven YT, Breukink BJ, Wagenaar JA, Van Pelt W. Risk factors for indigenous Campylobacter jejuni and Campylobacter coli infections in The Netherlands: a case–control study. Epidemiol Infect. 2010;138:1391–404.
6. Doorduyn Y, Van Den Brandhof WE, Van Duynhoven YT, Wannet WJ, Van Pelt W. Risk factors for Salmonella Enteritidis and Typhimurium (DT104 and non-DT104) infections in The Netherlands: predominant roles for raw eggs in Enteritidis and sandboxes in Typhimurium infections. Epidemiol Infect. 2006;134:617–26.
7. Banatvala N, Cramp A, Jones IR, Feldman RA. Salmonellosis in North Thames (East), UK: associated risk factors. Epidemiol Infect. 1999;122:201–7.
8. Wu HH, Chen YT, Shih CJ, Lee YT, Kuo SC, Chen TL. Association between recent use of proton pump inhibitors and nontyphoid salmonellosis: a nested case–control study. Clin Infect Dis. 2014;59:1554–8.
9. Garcia Rodriguez LA, Ruigomez A. Gastric acid, acid-suppressing drugs, and bacterial gastroenteritis: how much of a risk? Epidemiology. 1997;8:571–4.
10. de Jongh E, Numans ME, de Wit NJ, Heemstra-Borst CG, Geijer RM, Burgers JS. [Summary of the Dutch College of General Practitioners’ (NHG) practice guideline ‘Gastric symptoms’] Samenvatting van de NHG-standaard ‘Maagklachten’. Ned Tijdschr Geneeskd. 2013;157:A6101.
11. Shin JM, Sachs G. Pharmacology of proton pump inhibitors. Curr Gastroenterol Rep. 2008;10:528–34.
12. Huang JQ, Hunt RH. Pharmacological and pharmacodynamic essentials of H(2)-receptor antagonists and proton pump inhibitors for the practising physician. Best Pract Res Clin Gastroenterol. 2001;15:355–70.
13. Laheij RJ, Sturkenboom MC, Hassing RJ, Dieleman J, Stricker BH, Jansen JB. Risk of community-acquired pneumonia and use of gastric acid-suppressive drugs. JAMA. 2004;292:1955–60.
14. Tleyjeh IM, Bin Abdulhak AA, Riaz M, Alasmari FA, Garbati MA, AlGhamdi M, et al. Association between proton pump inhibitor therapy and clostridium difficile infection: a contemporary systematic review and meta-analysis. PLoS One. 2012;7:e50836.
15. Bavishi C, Dupont HL. Systematic review: the use of proton pump inhibitors and increased susceptibility to enteric infection. Aliment Pharmacol Ther. 2011;34:1269–81.
16. Bouwknegt M, van Pelt W, Kubbinga ME, Weda M, Havelaar AH. Potential association between the recent increase in campylobacteriosis incidence in the Netherlands and proton-pump inhibitor use an ecological study. Euro Surveill. 2014;19(32):21.
17. Leonard J, Marshall JK, Moayyedi P. Systematic review of the risk of enteric infection in patients taking acid suppression. Am J Gastroenterol. 2007;102:2047–56.
18. Sarker SA, Gyr K. Non-immunological defence mechanisms of the gut. Gut. 1992;33:987–93.
19. Foley SL, Johnson TJ, Ricke SC, Nayak R, Danzeisen J. Salmonella pathogenicity and host adaptation in chicken-associated serovars. Microbiol Mol Biol Rev. 2013;77:582–607.
20. Freedberg DE, Lebwohl B, Abrams JA. The impact of proton pump inhibitors on the human gastrointestinal microbiome. Clin Lab Med. 2014;34:771–85.
21. Masanta WO, Heimesaat MM, Bereswill S, Tareen AM, Lugert R, Groß U, et al. Modification of intestinal microbiota and its consequences for innate immune response in the pathogenesis of campylobacteriosis. Clin Dev Immunol. 2013;2013:526860.
22. Kohler H, Sakaguchi T, Hurley BP, Kase BA, Reinecker HC, McCormick BA. Salmonella enterica serovar Typhimurium regulates intercellular junction proteins and facilitates transepithelial neutrophil and bacterial passage. Am J Physiol Gastrointest Liver Physiol. 2007;293:G178–87.
23. Kedika RR, Souza RF, Spechler SJ. Potential anti-inflammatory effects of proton pump inhibitors: a review and discussion of the clinical implications. Dig Dis Sci. 2009;54:2312–7.
24. Brophy S, Jones KH, Rahman MA, Zhou SM, John A, Atkinson MD, et al. Incidence of Campylobacter and Salmonella infections following first prescription for PPI: a cohort study using routine data. Am J Gastroenterol. 2013;108:1094–100.
25. Hofman A, Brusselle GG, Darwish Murad S, van Duijn CM, Franco OH, Goedegebure A, The Rotterdam Study, et al. objectives and design update. Eur J Epidemiol. 2016;2015(30):661–708.
26. Hubbard AE, Ahern J, Fleischer NL, Van der Laan M, Lippman SA, Jewell N, et al. To GEE or not to GEE: comparing population average and mixed models for estimating the associations between neighborhood risk factors and health. Epidemiology. 2010;21:467–74.
27. Gardiner JC, Luo Z, Roman LA. Fixed effects, random effects and GEE: what are the differences? Stat Med. 2009;28:221–39.
28. Stricker BH, Stijnen T. Analysis of individual drug use as a time-varying determinant of exposure in prospective population-based cohort studies. Eur J Epidemiol. 2010;25:245–51.
29. Domingues AR, Pires SM, Halasa T, Hald T. Source attribution of human campylobacteriosis using a meta-analysis of case–control studies of sporadic infections. Epidemiol Infect. 2012;140:970–81.
30. Domingues AR, Pires SM, Halasa T, Hald T. Source attribution of human salmonellosis using a meta-analysis of case–control studies of sporadic infections. Epidemiol Infect. 2012;140:959–69.
31. Hurwitz A, Brady DA, Schaal SE, Samloff IM, Dedon J, Ruhl CE. Gastric acidity in older adults. JAMA. 1997;278:659–62.
32. Skirrow MB. A demographic survey of campylobacter, salmonella and shigella infections in England A Public Health Laboratory Service Survey. Epidemiol Infect. 1987;99:647–57.
33. Aomatsu M, Kato T, Kasahara E, Kitagawa S. Gender difference in tumor necrosis factor-alpha production in human neutrophils stimulated by lipopolysaccharide and interferon-gamma. Biochem Biophys Res Commun. 2013;441:220–5.